Chimerix (NASDAQ:CMRX) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.09, Fidelity Earnings reports. The firm had revenue of $0.37 million for the quarter, compared to the consensus estimate of $0.97 million. Chimerix had a negative return on equity of 34.94% and a negative net margin of 1,582.64%.
Shares of CMRX traded down $0.17 during trading hours on Friday, reaching $3.32. The stock had a trading volume of 84,193 shares, compared to its average volume of 215,341. Chimerix has a 12 month low of $3.11 and a 12 month high of $5.94. The stock has a market capitalization of $172.41 million, a price-to-earnings ratio of -2.20 and a beta of 1.20.
CMRX has been the topic of a number of research analyst reports. Zacks Investment Research raised Chimerix from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a report on Thursday, October 4th. Cowen reaffirmed a “hold” rating and issued a $6.00 target price on shares of Chimerix in a report on Thursday, October 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Chimerix in a report on Friday, September 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $6.75.
Institutional investors and hedge funds have recently made changes to their positions in the company. Leisure Capital Management bought a new position in shares of Chimerix in the 3rd quarter valued at $108,000. Wells Fargo & Company MN lifted its stake in shares of Chimerix by 46.1% in the 1st quarter. Wells Fargo & Company MN now owns 33,569 shares of the biopharmaceutical company’s stock valued at $175,000 after acquiring an additional 10,598 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Chimerix by 63.3% in the 2nd quarter. Acadian Asset Management LLC now owns 155,067 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 60,087 shares during the last quarter. Spark Investment Management LLC bought a new position in shares of Chimerix in the 2nd quarter valued at $917,000. Finally, Schwab Charles Investment Management Inc. lifted its stake in shares of Chimerix by 18.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 223,189 shares of the biopharmaceutical company’s stock valued at $1,063,000 after acquiring an additional 35,216 shares during the last quarter. Institutional investors own 71.85% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/11/10/chimerix-cmrx-releases-earnings-results.html.
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Featured Article: Stop Order Uses For Individual Investors
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.